The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...

Regionally adaptive governance, essential in the Indian context, remains inconsistent, with significant disparities between ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Innovation fails when every pilot starts from scratch; the chassis approach shows how to move fast with vendors while keeping ...

1. Risk: AI Monoculture (Shared Blind Spots). This is the most critical and overlooked systemic vulnerability. Building your ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

For years, Total Value Locked (TVL) has been the canary in DeFi's coalmine. When it was up, the sector was ‘thriving'. When it was down, DeFi was ‘in decline'. During 2025, that narrative began to ...

Accurate classification of wetland vegetation is essential for biodiversity conservation and carbon cycle monitoring. This study developed an adaptive ...

TL;DR: The Great Flood starts as a familiar Korean disaster film before mutating into an unsettling sci-fi meditation on emotional optimization and algorithmic storytelling. It’s messy, ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...